Independent fund research. Built on SEC filings.

How we research funds

Mutual fund · Allocation / Balanced · Aspiriant

Aspiriant Risk-Managed Equity Allocation Fund Advisor Shares (RMEAX)

Ticker RMEAX · · Holdings as of Jun 30, 2026

Expense ratio
0.95%$95/yr per $10k
5-yr return
+9.2%annualized
1-yr return
+17.7%as of Dec 2025
Net assets
$1.4Ball share classes
Holdings
144

Bottom line

Is RMEAX a good fund? The bottom line

RMEAX is the Advisor share class of Aspiriant Risk-Managed Equity Allocation Fund, a managed allocation / balanced mutual fund from Aspiriant.

Its expense ratio is 0.95% — about $95 a year on every $10,000 invested, more expensive than 55% of allocation / balanced funds we track.

It returned +17.7% over one year, +9.2% a year over five years, +8.8% a year over ten (as of Dec 31, 2025, per its prospectus).

With $1.4 billion in net assets and 144 holdings, its largest position is GMO Quality Fund (34.5%) and the top 10 make up 73.7% of the portfolio.

What stands out

  • 5-year return beat 92% of category peers
  • No front-end sales load

What to watch

  • Concentrated: top 10 holdings are 73.7% of assets

Updated Nov 19, 2026

What RMEAX invests in

The Aspiriant Risk-Managed Equity Allocation Fund (the Fund or Equity Allocation Fund) seeks to achieve long-term capital appreciation while considering federal tax implications of investment decisions.

Under normal conditions, the Equity Allocation Fund will invest at least 80% of its net assets (plus borrowings for investment purposes) in equity securities. The types of equity securities the Fund may invest in include common stock, preferred stock, and depositary receipts. The Fund also may invest in securities that provide exposure to equity securities ( i.e. , rights, warrants, and investment company shares). The Fund will hold a broad and diverse group of equity securities of companies in countries with developed and emerging markets, which are considered developed or emerging based upon the market definition used by the MSCI ACWI Index (the MSCI Index). The Fund may invest in companies of any market capitalization. The Fund seeks to achieve its investment objective by investing in securities that the Adviser believes offer the most attractive return vs. risk opportunities. The…

From the fund's prospectus (filed Jul 29, 2026).

RMEAX performance

Fund calendar-year total returns, 2015–2025 2015: −0.3%; 2016: +4.5%; 2017: +21.8%; 2018: −3.5%; 2019: +16.8%; 2020: +4.0%; 2021: +14.8%; 2022: −13.7%; 2023: +16.2%; 2024: +14.7%; 2025: +17.7% −0% 2015 +5% 2016 +22% 2017 −4% 2018 +17% 2019 +4% 2020 +15% 2021 −14% 2022 +16% 2023 +15% 2024 +18% 2025
Fund gain (+) Fund loss (−)
Average annual total returns
1 yr5 yr10 yr
RMEAX+17.7%+9.2%+8.8%
Allocation / Balanced median+11.0%+5.7%+6.7%

Source: Fund prospectus, as of Dec 31, 2025

Full RMEAX performance history →

What RMEAX costs

On a $10,000 investment, RMEAX's 0.95% expense ratio costs about $95 a year. The prospectus estimates $1,305 in total costs over 10 years (assuming 5% annual returns). The median allocation / balanced fund charges 0.91%.

See the full RMEAX fee table →

RMEAX top 10 holdings

#Holding% of fund
1GMO Quality Fund34.47%
2Schwab Fundamental Emerging Markets Equity ETF7.19%
3Rief Strategic Partners Fund6.44%
4Baillie Gifford Emerging Markets Equities Fund5.66%
5GMO Investments ICAV - GMO Equity Dislocation Investment Fund4.32%
6AQR Large Cap Defensive Style Fund3.83%
7Viking Global Equities LP3.41%
8JPMorgan Prime Money Market Fund3.18%
9iShares MSCI Global Min Vol Factor ETF2.84%
10iShares MSCI ACWI ETF2.39%

Source: SEC Form N-PORT, period ended Jun 30, 2026

The top 10 make up 73.7% of the fund. See all top 25 holdings and asset mix →

Alternatives to RMEAX

More funds like RMEAX →

RMEAX FAQ

What is the expense ratio of RMEAX?
RMEAX's expense ratio is 0.95%, which works out to about $95 a year for every $10,000 invested. The prospectus estimates total costs of $1,305 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is RMEAX a good investment?
It depends on your goals, but the data points to: 5-year return beat 92% of category peers; no front-end sales load; concentrated: top 10 holdings are 73.7% of assets. This is general information, not personalized advice.
What does RMEAX hold?
RMEAX's largest holdings are GMO Quality Fund (34.5%), Schwab Fundamental Emerging Markets Equity ETF (7.2%), Rief Strategic Partners Fund (6.4%), Baillie Gifford Emerging Markets Equities Fund (5.7%), GMO Investments ICAV - GMO Equity Dislocation Investment Fund (4.3%). It holds 144 positions in total as of Jun 30, 2026 (SEC Form N-PORT).
What is RMEAX's 5-year return?
RMEAX returned +9.2% a year over the five years ending Dec 31, 2025, and +8.8% a year over ten years. Past performance does not guarantee future results.
Does RMEAX have a sales load?
No. RMEAX has no front-end sales charge.
Who manages RMEAX?
RMEAX is offered by Aspiriant through Aspiriant Trust.